United Therapeutics Corporation (UTHR) is a leading biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients suffering from chronic and life-threatening diseases. Founded in 1996 by Martine Rothblatt, the company has its headquarters in Silver Springs, Maryland, USA.
UTHR primarily concentrates on therapeutic interventions for pulmonary arterial hypertension (PAH), a disorder characterized by elevated blood pressure in the arteries of the lungs, and certain associated conditions. The company has multiple marketed products for PAH including Remodulin, Tyvaso, and Adcirca that have effectively drawn a significant patient base. Additional applications for these technologies are under active development, including organ transplantation and cancer.
The company's commitment to innovation and medical research is evident in its strong and diverse product pipeline. It incorporates in-house development of novel drugs and devices as well as strategic collaborations with other research institutions and industry organizations. This focus on research and development is central to United Therapeutics’ strategy.
United Therapeutics has a solid financial structure underpinned by steady revenue generated from its portfolio of products. The company has shown a clear pattern of consistent growth since inception and has been able to deliver increasing returns to its shareholders. Further, the company has a robust patent portfolio which provides it with a competitive edge in the marketplace.
An essential component of UTHR’s corporate identity is a profound dedication to corporate social responsibility. The company takes the lead in several charitable and volunteer initiatives, like efforts to improve the lives of those affected by PAH, support for organ transplantation services, and promotion of women in the sciences.
A forward-thinking organization, United Therapeutics also invests in futuristic technologies. Its subsidiary, Lung Biotechnology PBC, works on revolutionary methods for manufacturing organs. The company is developing technologies to create an unlimited supply of transplantable organs to help save countless lives.
United Therapeutics is driven by the principle that no patient should die for lack of available medicine. Its deep dedication to this mission, combined with excellent management and a commitment to innovative research and development, makes United Therapeutics a leading player in the biotechnology industry.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
United Therapeutics Corp. has opened a $110 million sterile facility in Stewartville, Minnesota, dedicated to raising genetically modified pigs for xenotransplantation. This facility aims to address the critical shortage of human organs for transplant by providing compatible pig organs. Scientists highlight advances in gene editing and anti-rejection drugs as key drivers of progress in the field, with pigs being the preferred animal due to their scalability and lifespan.
H.C. Wainwright has resumed coverage on United Therapeutics (UTHR) with a "Buy" rating and set a new price target of $660.00. This analyst action was highlighted by Quantisnow, noting that previous UTHR headlines have resulted in varied stock movements, with a median change of 1.3%. The report also includes historical stock performance data after specific corporate announcements.